# From genes to therapy: navigating the complex landscape of neurofibromatosis management in Canada through advanced diagnostic, targeted therapies, and holistic care

**Authors:** Victor Shu Cheng Zhao

PMC · DOI: 10.1186/s13023-025-03793-2 · Orphanet Journal of Rare Diseases · 2025-08-05

## TL;DR

This paper discusses the challenges of managing neurofibromatosis in Canada and highlights the need for better diagnostic tools, targeted therapies, and holistic care.

## Contribution

The paper emphasizes the integration of advanced diagnostics, targeted treatments, and comprehensive support systems for managing neurofibromatosis in Canada.

## Key findings

- There is currently no dedicated NF clinic in Metro Vancouver, requiring patients to travel to Toronto for treatment.
- Recent advancements include gene therapy and MEK inhibitors, though their long-term effects are uncertain.
- Psychological interventions are crucial for addressing mental health challenges in NF patients.

## Abstract

Neurofibromatosis (NF) presents a significant clinical challenge due to its complex genetic basis, diverse clinical manifestation, and substantial impact on a patient’s quality of life (QoL). This paper explores the multifaceted approach required to manage NF in Canada, emphasizing the integration of advanced diagnostic tools, targeted treatments, and comprehensive support systems. Healthcare providers, researchers, patient advocacy groups, and policymakers must collaborate to ensure NF patients receive the best possible care and support. This disease poses devastating consequences to families, and there has been a lack of awareness of this issue in Vancouver and, generally, in British Columbia. Currently, there is no clinic dedicated explicitly to NF in Metro Vancouver, and patients diagnosed with this disease must be flown to Toronto to get treated. The process is costly and inefficient, demanding changes. Some recent improvements in the field of NF have been noted, such as the use of gene therapy and MEK inhibitors. However, the long-term effect of this treatment is largely unknown and should be viewed with caution. This underscores the importance of enhancing psychological interventions to address the mental health challenges faced by NF patients. Specific gene sequences for different types of NF have also been mentioned in the article to offer insights on potential targets for gene-editing technology like CRISPR. Through ongoing advancements in medical science and a commitment to patient-centered care, this paper envisions significant improvements in the management and treatment of this complex condition.

## Linked entities

- **Diseases:** neurofibromatosis (MONDO:0018975)

## Full-text entities

- **Genes:** MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}
- **Diseases:** NF (MESH:D017253)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12326665/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC12326665/full.md

---
Source: https://tomesphere.com/paper/PMC12326665